On Feb 10, 2024, the FDA granted Humacyte a priority review for its vascular trauma treatment, causing its shares to rise 13%.

On Saturday, 2024-02-10, the U.S. Food and Drug Administration (FDA) granted Humacyte a priority review for their vascular trauma treatment under development. As a result of this decision, Humacyte's shares saw a significant increase, rising by almost 13% to $3.53 on Friday. This growth marks a 21% increase in Humacyte's shares over the last 12 months.

February 09, 2024
3 Articles